Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 806-543-7 | CAS number: 215917-77-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2021-05-11 to 2021-06-03
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 022
- Report date:
- 2022
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 25 June 2018
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- August 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.31 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 30 May 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 1-(2-benzenesulfonamidophenyl)-3-phenylurea
- EC Number:
- 806-543-7
- Cas Number:
- 215917-77-4
- Molecular formula:
- C19H17N3O3S
- IUPAC Name:
- 1-(2-benzenesulfonamidophenyl)-3-phenylurea
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Han: WIST
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Toxi-Coop Zrt. Cserkesz u. 90., 1103 Budapest, Hungary
- Age at study initiation: ca. 10 weeks (females), 33-34 weeks (males for mating)
- Weight at study initiation: The group averages of the body weight of the females were as similar as possible on the first day of gestation (182-232 g)
- Fasting period before study: no
- Housing:
Before mating: 1-2 females per cage, 2 males per cage
During mating: 1 male and 1-2 females / cage
During gestation: 2 sperm positive females per cage, if not possible 1 sperm positive female per cage
- Diet: ad libitum, ssniff® SM Rat/Mouse-Zucht+Haltung" Autoclavable
complete feed for rats and mice – breeding " produced by ssniff Spezialdiäten GmbH, D-59494 Soest, Germany
- Water: ad libitum, tap water
- Acclimation period: 6 days for females
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.1 - 24.6
- Humidity (%): 44 - 61
- Air changes (per hr): above 10
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: Methylcellulose (1 %)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The test item was formulated in the vehicle (Methylcellulose (1 %)) at concentrations of 20 mg/mL, 60 mg/mL and 200 mg/mL. Formulations were prepared in the formulation laboratory of the Test Facility beforehand for not longer than 2 days and stored in a refrigerator (5±3 °C) until use. A constant treatment volume of 5 mL dose preparation/kg body weight was administered in all groups. The individual volume of the treatment was based on the most recent individual body weight of the animals.
VEHICLE
- Justification for use and choice of vehicle: The test item is not soluble in water. Therefore, Methylcellulose (1 %) was used for preparing formulations appropriate for oral administration. Methylcellulose (1 %) is a suitable vehicle for the test item - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The mean concentration of formulation samples was in the range of 106-109 % compared to the corresponding nominal concentration (within the acceptance criteria). The formulations were considered as homogenous since the difference of the measured concentrations of parallel samples was not more than 15% (1.2-3.3%).
- Details on mating procedure:
- - Impregnation procedure: cohoused
- M/F ratio per cage: one male: one to two females
- Length of cohabitation: 2 - 4 hours
- Further matings after two unsuccessful attempts: no
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
- Any other deviations from standard protocol: no - Duration of treatment / exposure:
- The sperm positive females were treated from gestational day 5 to 19.
- Frequency of treatment:
- daily
- Duration of test:
- 15 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 26
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were selected based on the results of the dose range finding study, where oral treatment of pregnant Han: WIST rats with the dose levels of 1000, 300 and 100 mg/kg bw/day of NKK-1304 revealed neither maternal nor fetal toxicity.
- Fasting period before blood sampling for (rat) dam thyroid hormones: no
- Time of day for (rat) dam blood sampling: in the morning on the day of necropsy within a short timeframe (not exceeding two hours).
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: once daily for behavior and general condition; twice daily for morbidity and mortality
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: The body weight of the female rats was measured at least once in the pre-mating period, but was not statistically evaluated. Body weight of sperm positive females was measured on gestation days 0, 3, 5, 8, 11, 14, 17 and 20 (accuracy of 1 g). The corrected body weight was calculated for the 20th day of pregnancy.
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
- Food consumption was measured between gestation days 0 to 3, 3 to 5, 5 to 8, 8 to 11, 11 to 14, 14 to 17 and 17 to 20 by re-weighing the non-consumed diet (accuracy: 1 g).
WATER CONSUMPTION AND COMPOUND INTAKE: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: Thyroid glands together with the parathyroid glands of all sperm positive females were weighed and recorded with a precision of 0.001 g after fixation in 4 % (v/v) buffered formaldehyde solution. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Blood sampling:
- - Plasma: No
- Serum: Yes
- Volume collected: least 1.0 mL blood
-Other: Serum samples were divided into two aliquots (one for FT3 and FT4 as well as one for TSH level determination) and stored between -15 to -30 °C - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: Yes: half per litter
- Anogenital distance of all live rodent pups: The anogenital distance (AGD) of each fetus was determined (accuracy 1 mm). - Statistics:
- The heterogeneity of variance between groups was checked by Bartlett's homogeneity of variance test. Where no significant heterogeneity is detected, a one-way analysis of variance (ANOVA) was carried out. If the obtained result positive, Duncan's Multiple Range test was used to assess the significance of inter-group differences. Where significant heterogeneity found, the normal distribution of data was examined by Kolmogorov-Smirnov test. In case of a none-normal distribution, the non-parametric method of Kruskal-Wallis One-Way analysis of variance was used. If there is a positive result, the inter-group comparisons are performed using the Mann-Whitney U-test. Chi2 test was performed if feasible.
- Indices:
- - Pre-implantation loss
- Post-implantation loss
- Sex distribution
- External abnormalities/litter
- Visceral abnormalities/litter
- Skeletal abnormalities/litter - Historical control data:
- Yes, provided by test laboratory.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One female in the 100 mg/kg bw/day group was moribund and euthanized in the course of the study on g.d. 11. This female had clinical signs from g.d. 9 such as hunched back, piloerection and reduced activity as well it was lying on the side and had dyspoea on g.d. 11. Considering that none of the other animals died, was moribund or had clinical signs in the experimental groups, this was judged as unrelated to the test item.
- Mortality:
- mortality observed, non-treatment-related
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The body weight/gain (including corrected body weight/gain) values were similar in the groups.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no reductions in the food consumption observed. In the treatment period, there were no statistically significant differences indicated. Before the treatment period, from g.d. 3 to 5, a slightly but statistically significantly higher (p<0.05) mean food consumption was seen in the 300 and 1000 mg/kg bw/day which was considered as biologically not relevant.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences observed in the measured TSH, FT3 and FT4 hormone levels in the control, 100, 300 and 1000 mg/kg bw/day groups.
- Clinical biochemistry findings:
- not examined
- Endocrine findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The mean thyroid weight (including relative values) was statistically significantly lower (0.0265 g, p<0.05) in the 1000 mg/kg bw/day dose group. However, according to the historical control database, the value was above the historical control range (0.0219-0.0224 g). Considering this, and that there were no differences in the thyroid and TSH hormone levels indicated, as well as there were no lesions found in the thyroids at histopathology, it was not considered as treatment-related.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Dilated renal pelvis occurred with low incidences and without a dose response in one control female. Therefore, these were considered as unrelated to the test item.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- According to the expert’s evaluation, there were no test item- related lesions observed upon histological examinations of the thyroid tissue in all treatment groups compared to the control. There were no other organs examined since no lesions were detected in the treatment groups during necropsy.
- Histopathological findings: neoplastic:
- not examined
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no increase indicated in the mean of pre- and post-implantation loss. According to the Chi square evaluation, the number of pre-implantation loss was statistically significantly lower in the 100 mg/kg bw/day dose group and statistically significantly higher in the 300 mg/kg bw/day dose group without a dose response, hence not considered as treatment related.
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Changes in number of pregnant:
- no effects observed
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: highest dose tested
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- There were no differences in the body weight of the fetuses.
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The number of male fetuses was statistically significantly higher, and the number of female fetuses statistically significantly lower in the 300 mg/kg bw/day group versus control. This was considered as not relevant, since the sex distribution was near to 50-50%.
- Changes in litter size and weights:
- no effects observed
- Anogenital distance of all rodent fetuses:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The number of litters with malformed fetuses was 2/23, 1/22, 1/23 and 1/23 in the control, 100, 300 and 1000 mg/kg bw/day groups respectively. There were no statistically significant differences in the incidence of malformations over all dosing groups.
The number of evaluated fetuses was 240, 241, 238 and 233 in the control, 100, 300 and 1000 mg/kg bw/day groups, respectively.
Variations: There were three pale fetuses found in the control and one with neck edema in the 100 mg/kg bw/day group.
Malformations: One fetus had umbilical hernia in the control group.
Growth retardation (small fetuses): There was no significant of dose related difference in the incidence of small fetuses.
Placentas, amniotic fluid: In one litter (in the same as with the three pale fetuses), the amniotic fluid was brownish and two of the placentas had clotted bloody margin in the control group.
Considering the low incidences at external examination, and lack of dose response, the findings were not attributed to an effect of the test item. - Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The number of examined fetuses was 121, 121, 119 and 115 in the control, 100, 300 and 1000 mg/kg bw/day groups, respectively.
There was no statistically significant increase observed in the skeletal abnormalities (variations and malformations).
Malformations:
There was one malformed fetus found in each group including control.
One fetus had vertebra agenesis (5 lumbar vertebrae) and a misshapen LI vertebra in the 300 mg/kg bw/day group. This was found in the same litter with the fetus with hydronephrosis.
One fetus had bent scapula in the control group. One fetus had also bent scapula and in addition bent radius, ulna, femur, tibia and fibula in the 100 mg/kg bw/day dose group.
One fetus had hyperflexion of the left forelimb in the 1000 mg/kg bw/day group.
Considering the low incidences or lack of dose response, the skeletal findings were not proved as treatment related.
Variations:
Delayed ossification of skull bones, sternebra, vertebrae, pelvic girdle, metacarpal/metatarsal, as well as slightly open palatine, misaligned or bipartite ossification of sternebra, wavy ribs or interrupted 14th rib, bipartite or dumb-bell shaped ossification of vertebral centra as well as slightly bent scapula were observed without statistically significant differences among the dose groups. - Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The number of examined fetuses was 119, 121, 119 and 118 in the control, 100, 300 and 1000 mg/kg bw/day groups, respectively. There were no statistically significant increases in the incidence of visceral variations and malformations.
Variations:
Slightly dilated IIIrd ventricle was recorded in one fetus in the 300 mg/kg bw/day group.
Bilateral hydroureter was found in two fetuses in the 100 mg/kg bw/day group. Hydroureter accompanied with dilated renal pelvis was observed in one fetus in the control and one in the 100 mg/kg bw/day group.
Malformations
Marked hydroureter and in addition hydronephrosis was observed in one fetus in the 300 mg/kg bw/day group.
Considering the low incidences or lack of dose response, the findings at visceral examination were not judged as treatment related.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity including teratogenicity
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: highest dose tested
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Based on the observations the NOAELs from a OECD TG 414 study in rats were determined as follows:
NOAEL (maternal toxicity): 1000 mg/kg bw/day
NOAEL (developmental toxicity including teratogenicity):1000 mg/kg bw/day - Executive summary:
The substance was examined for its possible prenatal developmental toxicity in a study according OECD TG 414/GLP. Groups of 26 sperm-positive female Han: of Wistar origin rats were treated with the test item by oral administration daily at three dose levels of 100, 300 and 1000 mg/kg bw/day respectively from day 5 up to and including day 19 post coitum. A control group of 26 sperm positive females was included and the animals were given the vehicle 1% aqueous methylcellulose. The treatment volume was 5 mL/kg bw.
A sufficient stability and homogeneity in the chosen vehicle were verified over the range of relevant concentrations at the appropriate frequency of preparation. The substance in 1% aqueous methylcellulose was stable at room temperature for at least one day and for three days in the refrigerator (5 ± 3 °C) at the concentrations of 20 and 250 mg/mL. Analytical control of dosing solutions was performed during the first and last week of treatment. Concentrations of the test item in the dosing formulations varied in the acceptable range between 106 and 109 % of nominal concentrations at both analytical occasions confirming proper dosing.
During the study, mortality was checked and clinical observations were performed. Body weight and food consumption of the dams were also recorded. The day, when sperm was detected in the vaginal smear, was regarded as day 0 of gestation. Blood sampling for determination of thyroid hormones FT3 and FT4 as well as TSH, Caesarean section and gross pathology were performed on gestational day 20. Thyroids were weighed and evaluated histologically. The number of implantations, early and late resorptions, live and dead fetuses in each uterine horn and the number of corpora lutea were recorded. Each fetus was weighed and examined for sex and gross external abnormalities. The placentas were weighed and examined externally. External fetal sex was determined by gross pathological examination and compared with internal (gonadal) sex in all fetuses (examined for both skeletal and soft tissue alterations). The anogenital distance was measured. In addition, indication of incomplete testicular descent / cryptorchidism was noted in male fetuses.
About half of each litter was preserved for visceral examination and the other half of the litters were preserved for skeletal evaluation. At visceral examination the bodies were micro dissected by means of a dissecting microscope. The heads were examined by Wilson's free-hand razor blade method.
After cartilage-bone staining the skeletons were examined by means of a dissecting microscope. All abnormalities found during the fetal examinations were recorded.
Results
In total, on gestation day 20 there were 23 evaluated litters in the control, 300 and 1000 mg/kg bw/day groups, respectively, as well as 22 in the 100 mg/kg bw/day group.
One non pregnant female was moribund in the course of the study in the 100 mg/kg bw/day group after clinical signs such as hunched back, piloerection and reduced activity, as well as dyspnoea and lying on the side due to an unknown reason. Necropsy revealed no macroscopic changes in the organs.
The other animals had no clinical signs and there were no treatment related pathological changes found.
The food consumption and body weight of the animals was similar in each group.
The mean of thyroid weight was statistically significantly lower in the 1000 mg/kg bw/day group (p<0.05), however the value was above the historical control level. Moreover, the treatment did not result in histological changes of the thyroid gland in any of the dose groups and the measured hormone levels were similar in the groups.
There were no treatment related differences observed in the pre- and post implantation loss. The number of implantations and viable fetuses as well as their sex distribution was similar in the groups.
The fetal weight was equal in the groups. There were no significant differences in the ano-genital distance and placental weight parameters. There were no significant differences in the incidence of body weight retarded (smaller) fetuses.
At fetal examinations, there were no significant differences in the incidence of malformations and variations during external, visceral and skeletal examinations at any dose level.
Conclusion
Oral treatment of pregnant Han: Wistar rats from gestation day 5 up to day 19 (the day before Caesarean section) with the substance at the dose levels of 1000, 300 and 100 mg/kg bw/day caused no mortality, clinical signs and necropsy or histopathology changes of the maternal animals. The treatment with the test item had no impact the food consumption and body weight/corrected body weight/gain. Thyroid-related parameters (FT3, FT4 TSH hormone levels and histopathology) were not affected by treatment. Statistically significantly lower thyroid weight in the 1000 mg/kg bw/day dose group was not attributed to the treatment based on historical control data and lack of changes in the hormone levels or absence of histopathology lesions. The test item caused no differences in the intrauterine parameters. No test item related differences in the incidence of malformations and variations as well as growth retardation or placental changes over all dosing groups were observed.
Based on the observations the No Observed Adverse Effect Level (NOAEL) was determined as follows:
NOAEL (maternal toxicity): 1000 mg/kg bw/day
NOAEL (developmental toxicity
including teratogenicity): 1000 mg/kg bw/day
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.